IMRT时代头颈部鳞癌再程放疗患者选择优化:MIRI多机构队列研究
该多机构队列研究纳入412例既往照射野(≥40 Gy)内复发或第二原发头颈鳞癌并接受IMRT再程放疗(≥40 Gy)的患者,中位再程IMRT剂量60 Gy,76%联合化疗。递归 partitioning 分析(RPA)识别出3个总生存期(OS)显著不同的预后亚组(P<.001),2年OS分别为61.9%、40.0%和16.8%,可指导患者选择与临床试验设计。
要点
- RPA将患者分为3个OS显著不同的亚组,2年OS分别为61.9%、40.0%和16.8%(P<.001)。
- RPA III组患者无论是否手术,均不适合接受长时间的化放疗。
- 再程IMRT的3级及以上急性毒性发生率为19%,2年3级及以上晚期毒性累积发生率为14.2%。
核心结论
- 基于IMRT的再程放疗结局可为临床提供预期,RPA分类识别的3个亚组可指导治疗选择和临床试验设计。
- RPA III组患者无论切除状态如何,均不是长时间化放疗的理想候选者。
研究设计与样本
- 多机构队列研究,纳入7家机构412例既往照射野(≥40 Gy)内复发或第二原发头颈鳞癌接受IMRT再程放疗(≥40 Gy)的患者。
- 采用Gray竞争风险法计算局部区域失败和晚期毒性,Cox比例风险回归筛选与OS相关的因素并纳入递归 partitioning 分析(RPA)。
主要发现
- 再程IMRT中位剂量为60 Gy,两次放疗中位间隔为2.4年,76%患者接受化疗。
- 3级、4级和5级急性毒性发生率分别为19%、4.4%和1.2%。
- 校正复发或死亡竞争风险后,2年3级及以上晚期毒性累积发生率为14.2%。
- RPA识别3个OS显著不同且同质的预后亚组(P<.001):I组为距首次放疗>2年且肿瘤已切除者,2年OS 61.9%。
- II组为距首次放疗>2年但肿瘤未切除者,或距首次放疗≤2年且不依赖喂食管或气管造口者,2年OS 40.0%;其余患者为III组,2年OS 16.8%。
关键数值与推荐
- RPA I组:距首次放疗>2年且肿瘤已切除,2年OS 61.9%。
- RPA II组:距首次放疗>2年但肿瘤未切除,或距首次放疗≤2年且不依赖喂食管或气管造口,2年OS 40.0%。
临床怎么用
- 可依据RPA分类(距首次放疗时间、肿瘤切除状态、喂食管或气管造口依赖)评估再程放疗预后并选择患者。
- RPA III组患者无论是否手术,均不宜接受长时间化放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The therapeutic ratio of reirradiation for recurrent or second primary (RSP) squamous carcinoma of the head and neck may be improved in the intensity modulated radiation therapy (IMRT) era. However, patient selection for reirradiation remains challenging. We performed a multi-institution cohort study to investigate modern outcomes after IMRT-based reirradiation and to identify prognostic subgroups. PATIENTS AND METHODS: Patients with RSP squamous carcinoma originating in a previously irradiated field (≥40 Gy) who underwent reirradiation with IMRT (≥40 Gy re-IMRT) were included. Locoregional failure and late toxicity were calculated using the Gray competing risk method. Cox proportional hazards regression was used to identify factors associated with overall survival (OS). Factors associated with OS were entered into a recursive partitioning analysis (RPA) for OS. RESULTS: From 7 institutions, 412 patients were included. The median dose of re-IMRT was 60 Gy, and the median time between RT courses was 2.4 years. Chemotherapy was used in 76% of patients. The rates of grade ≥3, grade ≥4, and grade 5 acute toxicities were 19%, 4.4%, and 1.2%, respectively. The 2-year cumulative incidence of grade ≥3 late toxicity adjusted for the competing risks of recurrence or death was 14.2%. RPA identified 3 prognostic subgroups with distinct and homogenous OS (P<.001): class I included patients >2 years from their initial course of RT with resected tumors (2-year OS, 61.9%); class II included patients >2 years with unresected tumors or those ≤2 years and without feeding tube or tracheostomy dependence (2-year OS, 40.0%), and the remaining patients formed class III (2-year OS, 16.8%). Fifty-nine percent of class III patients underwent postoperative re-irradiation. CONCLUSIONS: This study informs outcomes and expectations with IMRT-based reirradiation. The RPA classification identifies 3 distinct subgroups, which can guide patient selection for therapy and clinical trial design. RPA class III patients are not ideal candidates for protracted chemoradiation regardless of resection status.
引用
- Ward MC, Riaz N, Caudell JJ, et al. Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. Int J Radiat Oncol Biol Phys. 2017. PMID: 28865925. doi:10.1016/j.ijrobp.2017.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。